LEONIE PRINCE: Open Payments
NPI 1922218569 · HACKENSACK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,662 in 141 payments from 10 companies in 2025. Trend: 2023 $857 · 2024 $961 · 2025 $1,662
Food & beverage: $1,558Education: $104
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 62 | $543 |
| Teva Pharmaceuticals USA, Inc. | 32 | $453 |
| Otsuka America Pharmaceutical, Inc. | 12 | $195 |
| Alkermes, Inc. | 10 | $190 |
| E.R. Squibb & Sons, L.L.C. | 17 | $151 |
| Almatica Pharma LLC | 3 | $45 |
| Lundbeck LLC | 2 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Janssen Pharmaceuticals, Inc | 1 | $16 |
| ABBVIE INC. | 1 | $16 |
Products named: INGREZZA, AUSTEDO XR, ARISTADA, COBENFY, ABILIFY ASIMTUFII, REXULTI, LOREEV XR, UZEDY.
Industry payments across NJ — which companies pay providers there.
